Christopher Melani, MD

home / authors / christopher-melani-md

Articles

Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL

Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL

Christopher Melani, MD
December 19th 2023

Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.

About the ViPOR Regimen in Aggressive Lymphomas

About the ViPOR Regimen in Aggressive Lymphomas

Christopher Melani, MD
December 11th 2022

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Discussing the ViPOR Regimen in Mantle Cell Lymphoma

Discussing the ViPOR Regimen in Mantle Cell Lymphoma

Christopher Melani, MD
September 20th 2022

Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.

ViPOR Regimen Shows High Complete Response Rate in MCL Cohort

ViPOR Regimen Shows High Complete Response Rate in MCL Cohort

Christopher Melani, MD
August 30th 2022

Christopher J. Melani, MD, discusses the results of a trial investigating a combination regimen in a cohort of patients with mantle cell lymphoma.

Revolutionizing Treatment for Patients With Relapsed/Refractory or Untreated MCL

Revolutionizing Treatment for Patients With Relapsed/Refractory or Untreated MCL

Christopher Melani, MD
June 23rd 2022

Christopher Melani, MD, discusses the unmet needs remaining in the mantle cell lymphoma space.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 21st 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 21st 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 21st 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC
Published: November 17th 2024 | Updated: November 21st 2024
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 21st 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma